
Ready to start planning your care? Call us at 800-525-2225 to make an appointment.







MOLECULAR PHARMACOLOGY PROGRAM

The David Scheinberg Lab

Open Positions

Molecular Pharmacology Program

Research



David A. Scheinberg, MD, PhD
Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic
Discovery

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now

being tested in Phase II human trials (*Blood*, 2010), and a vaccine to WT1 in Phase III trials. Read full article in *Science*.

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (*Science Trans. Med., 2013*), (*Nature Biotech.*, 2015), as well as prototype targeted nano-machines (*Nature Nano, 2013*), and cellular micropharmacies (*Nature Chem. Biol., 2021*).

Research Projects

Projects



Featured News



At Work: Center for Experimental Therapeutics Chair David Scheinberg

A second-generation physician-scientist, David Scheinberg specializes in caring for patients with leukemia — and developing new ways to treat it.

ANNOUNCEMENT



Innovative Partnership Will Speed Drug Discovery and Development

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

Scientists ID Antibody That Might Boost Cancer Therapy

Physician-scientist David Scheinberg discussed his discovery of a unique monoclonal antibody, a molecule that can be engineered to target specific prot...

View All Featured News

Publications Highlights

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science translational medicine. 2013;5(176):176ra33. Doi: 10.1126/scitranslmed.3005661. PubMed. PMCID: PMC3963696.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O'Reilly RJ, Scheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature biotechnology. 2015;33(10):1079-86. Doi: 10.1038/nbt.3349. PubMed PMID: 26389576; PMCID: PMC4600043.


View All Publications

People




The David Scheinberg Lab

Research Assistant




Michael R. **McDevitt**




Laboratory Member




Annelisa Cornel Research Fellow



Michael X. Lau **Pediatric** Hematology/Oncology






Zita Aretz Graduate Student






Josh Jaeyop Lee Hematology/Oncology Fellow





Winson Cai Graduate Student



Keifer Kurtz **Graduate Student**



Qianqian (Skylar) Lin **Graduate Student**



Manish Malviya Senior Research Scientist



Jeremy P.
Meyerberg
Research Technician




Stephanie
Pierre
Graduate Student



Sarah Qureshy Medical Student Research Fellow Education



Ekaterina Revskaya Senior Research Scientist



Kristen Vogt

Graduate Student

Patrick Wallisch Graduate Student

Lab Alumni

+

Lab Affiliations

+

Lab News & Events

Journal Club & Photo Album

Get in Touch

Scheinbd@mskcc.org
Lab Head Email

646-888-2190 Office Phone

646-888-2205Lab Phone

Lab Resources

+

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

David A. Scheinberg discloses the following relationships and financial interests:

Actinium

Equity; Intellectual Property Rights; Professional Services and Activities

Arvinas, Inc.

Equity

Atengen, Inc.

Equity; Professional Services and Activities (Uncompensated)

Bridge Medicines

Professional Services and Activities (Uncompensated)

Colmmune, Inc.

Equity; Intellectual Property Rights; Professional Services and Activities

Eureka Therapeutics Inc

Equity; Professional Services and Activities

Great Point Partners

Equity; Professional Services and Activities

Iovance Biotherapeutics, Inc.

Equity

Lantheus Medical Imaging, Inc.

Equity

OncoPep, Inc.

Professional Services and Activities

Pfizer, Inc.

Equity; Professional Services and Activities

Repertoire Immune Medicines, Inc.

Professional Services and Activities

Sapience Therapeutics, Inc.

Equity; Fiduciary Role / Position

Sellas Life Science Group

Equity; Fiduciary Role / Position; Intellectual Property Rights

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies <u>here</u>. For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at <u>ecoi@mskcc.org</u>.

View all disclosures



Communication preferences

Cookie preferences

Legal disclaimer

Accessibility Statement

Privacy policy

Public notices

© 2024 Memorial Sloan Kettering Cancer Center